SCHEMBL80567

SCHEMBL80567

[c]1ccc2cnncc2c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL129202 0.76
SCHEMBL71297 0.74
SCHEMBL455076 0.73
SCHEMBL18036 0.73 KDM4E (0.36)
SCHEMBL448776 0.73
SCHEMBL18990 0.73 PRKCZ (0.37)
SCHEMBL3835810 0.70
SCHEMBL3834527 0.70
SCHEMBL70257 0.69
SCHEMBL559813 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2085 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365620-A1 CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-11-16 US claimed
US-20230201200-A1 Methods for Treating Huntington’s Disease PTC THERAPEUTICS INC (US) 2023-06-29 US claimed
CN-114773249-A Compounds, pharmaceutical compositions and methods for treating inflammatory diseases 艾匹克治疗公司 2022-07-22 CN claimed
US-11072582-B2 Substituted pyrrolidines as G-protein coupled receptor 43 agonists EPICS THERAPEUTICS (BE) 2021-07-27 US claimed
US-20210054020-A1 CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-02-25 US claimed
EP-3154941-B1 SMALL MOLECULE LFA-1 INHIBITORS ALLOCYTE PHARMACEUTICALS AG (CH) 2021-01-20 EP claimed
EP-3752518-A1 CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF USE Dana Farber Cancer Institute, Inc. (US) 2020-12-23 EP claimed
US-20200369715-A1 CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-11-26 US claimed
US-20200347016-A1 SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS EPICS THERAPEUTICS (BE) 2020-11-05 US claimed
EP-3610872-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES EPICS THERAPEUTICS (BE) 2020-02-19 EP claimed
EP-0751944-A1 THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1997-01-08 EP claimed
EP-0385662-B1 Heterocycles with inhibitory activity of 5-lipoxygenase ZENECA LTD (GB) 1995-12-13 EP claimed
EP-0385663-B1 Heterocyclic cycloalkanes as inhibitors of 5-lipoxygenase ZENECA LTD (GB) 1995-12-06 EP claimed
WO-1995026347-A1 THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1995-10-05 WO claimed
EP-0420511-B1 Heterocyclic derivatives ICI PLC (GB) 1994-08-17 EP claimed
EP-0381375-B1 HETEROCYCLIC DERIVATIVES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-11-11 EP claimed
EP-0420511-A2 Heterocyclic derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-04-03 EP claimed
EP-0385663-A2 Heterocyclic cycloalkanes as inhibitors of 5-lipoxygenase ZENECA LIMITED (GB) 1990-09-05 EP claimed
EP-0385662-A2 Heterocycles with inhibitory activity of 5-lipoxygenase ZENECA LIMITED (GB) 1990-09-05 EP claimed
EP-0381375-A1 Heterocyclic derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-08-08 EP claimed